 Flutamide is also no longer recommended due to excessive risk of hepatotoxicity and liver failure in men with prostate cancer.For these reason, newer and safer like bicalutamide have largely replaced flutamide and nilutamide, and are now used for relevant indications instead.As selective antagonists, flutamide, nilutamide, and bicalutamide have the same mechanism of action, and bicalutamide has similar or greater efficacy to flutamide and nilutamide as an antiandrogen.